98%
921
2 minutes
20
Introduction: To examine the scope of existing literature on the conceptualization, use, and outcomes associated with compassion in the care of youth with childhood-onset disabilities.
Methods: A protocol was developed based on the Joanna Briggs Institute (JBI) scoping review method. MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, and EBSCOhost CINAHL, were searched.
Results: Eight studies were selected for inclusion; four used quantitative methodology, and four used qualitative methods. Compassion was not defined or in any of the included studies. The concept of self-compassion was explicitly defined only for parents of youth with childhood-onset disabilities in three studies . The most reported outcome measure was self-compassion in parents of youth with childhood-onset disabilities. Self-compassion among parents was associated with greater quality of life and resiliency and lower stress, depression, shame and guilt.
Discussion: There is limited evidence on the conceptualization, use, and outcomes associated with compassion among youth with childhood-onset disabilities. Self-compassion may be an effective internal coping process among parents of youth with childhood-onset disabilities. Further research is required to understand the meaning of compassion to youth with childhood-onset disabilities, their parents and caregivers.
Systematic Review Registration: https://doi.org/10.17605/OSF.IO/2GRB4.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11192198 | PMC |
http://dx.doi.org/10.3389/fpsyg.2024.1365205 | DOI Listing |
J Rheumatol
September 2025
A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
Objective: This study investigates individual and socio-ecological resilience and their relationship with sociodemographic and disease characteristics, and psychosocial patient-reported outcomes in childhood-onset systemic lupus erythematosus (cSLE).
Methods: We conducted a cross-sectional study of patients with cSLE ages 11-22 years at a Canadian tertiary center from October 2021-July 2024. The Connor-Davidson Resilience Scale (CD-RISC 10) assessed individual resilience.
Children (Basel)
July 2025
David Geffen School of Medicine, Pediatric Rheumatology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Youth with chronic rheumatologic diseases undergo medical experiences that can lead to post-traumatic stress disorder (PTSD). Understudied in pediatric rheumatology, medical PTSD can be significantly distressing and impairing. This study explored the prevalence of medical PTSD symptoms in youth with chronic inflammatory arthritis and associated factors, including pain, disease activity, mental health history, and anxiety sensitivity.
View Article and Find Full Text PDFDisabil Rehabil
August 2025
Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Canada.
Background: Health care providers face many challenges with delivering care in rural areas. However, little is known about their experiences of providing care to marginalized populations, such as children with disabilities. The purpose of this study was to explore the experiences of health care providers serving rural children with disabilities.
View Article and Find Full Text PDFPediatr Nephrol
August 2025
Paediatric Nephrology Centre, Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR.
Background: Neuropsychiatric systemic lupus erythematosus (NPSLE) and lupus nephritis (LN) are two major, life-threatening complications in childhood-onset SLE (cSLE). Data regarding the epidemiology and prognosis of children with concurrent NPSLE and LN remain scarce. This study aimed to investigate the clinical characteristics, associated factors, and outcomes of NPSLE in Chinese children with LN.
View Article and Find Full Text PDFRheumatology (Oxford)
August 2025
Institute of Child Health, University College London, London, UK.
Paediatric rheumatic diseases (RMDs) are characterised by dysregulation of the immune system functions due to a combination of genetic, epigenetic and environmental factors. In many cases, children and young people (CYP) with RMDs require long-term pharmacological interventions to control their symptoms, minimise the risk of disease relapse and organ damage, and ultimately preserve their quality of life. The last decades have seen significant progress in the expansion of therapeutic options licensed or available off-license for CYP with RMDs, and an unprecedented number of paediatric interventional clinical trials testing new therapies.
View Article and Find Full Text PDF